Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Free Cash Flow 2010-2024 | CYDY

CytoDyn free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
  
CytoDyn Annual Free Cash Flow
2023 -25.11
2022 -77.72
2021 -117.70
2020 -68.85
2019 -50.49
2018 -29.90
2017 -26.74
2016 -24.82
2015 -12.04
2014 -7.41
2013 -3.40
2012 -4.39
2011 -1.83
2010 -1.77
2009 -1.29
CytoDyn Quarterly Free Cash Flow
2024-02-29 -9.33
2023-11-30 -7.00
2023-08-31 -4.50
2023-05-31 -25.11
2023-02-28 -21.70
2022-11-30 -15.48
2022-08-31 -11.07
2022-05-31 -77.72
2022-02-28 -71.71
2021-11-30 -60.65
2021-08-31 -31.75
2021-05-31 -117.70
2021-02-28 -84.87
2020-11-30 -61.20
2020-08-31 -41.01
2020-05-31 -68.85
2020-02-29 -39.53
2019-11-30 -21.99
2019-08-31 -15.20
2019-05-31 -50.49
2019-02-28 -40.96
2018-11-30 -26.20
2018-08-31 -8.97
2018-05-31 -29.90
2018-02-28 -22.92
2017-11-30 -12.89
2017-08-31 -7.00
2017-05-31 -26.74
2017-02-28 -19.57
2016-11-30 -10.78
2016-08-31 -6.26
2016-05-31 -24.82
2016-02-29 -19.57
2015-11-30 -8.52
2015-08-31 -5.25
2015-05-31 -12.04
2015-02-28 -7.78
2014-11-30 -5.29
2014-08-31 -2.59
2014-05-31 -7.41
2014-02-28 -5.65
2013-11-30 -2.91
2013-08-31 -0.81
2013-05-31 -3.40
2013-02-28 -2.40
2012-11-30 -1.17
2012-08-31 -0.41
2012-05-31 -4.39
2012-02-29 -2.89
2011-11-30 -1.30
2011-08-31 -0.55
2011-05-31 -1.83
2011-02-28 -1.35
2010-11-30 -0.80
2010-08-31 -0.31
2010-05-31 -1.77
2010-02-28 -1.16
2009-11-30 -0.82
2009-08-31 -0.29
2009-05-31 -1.29
2009-02-28 -0.92
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.237B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $77.602B 31.55
Chugai Pharmaceutical (CHGCY) Japan $49.613B 22.18
Takeda Pharmaceutical (TAK) Japan $41.523B 8.41
Merck (MKGAF) Germany $22.955B 22.26
Astellas Pharma (ALPMY) Japan $18.079B 28.54
Sandoz Group AG (SDZNY) Switzerland $15.083B 0.00
Neurocrine Biosciences (NBIX) United States $14.029B 38.40
Shionogi (SGIOY) Japan $13.012B 11.31
United Therapeutics (UTHR) United States $12.104B 12.90
Catalent (CTLT) United States $9.921B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.530B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.686B 7.35
Revolution Medicines (RVMD) United States $6.261B 0.00
Orion OYJ (ORINY) Finland $5.645B 23.81
Ionis Pharmaceuticals (IONS) United States $5.442B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.396B 0.00
Madrigal Pharmaceuticals (MDGL) United States $4.893B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.743B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.090B 0.00
Corcept Therapeutics (CORT) United States $2.865B 25.96
PTC Therapeutics (PTCT) United States $2.853B 0.00
Dyne Therapeutics (DYN) United States $2.728B 0.00
Indivior (INDV) United States $2.395B 11.35
Summit Therapeutics (SMMT) United States $2.373B 0.00
Recursion Pharmaceuticals (RXRX) United States $2.177B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.991B 11.32
Catalyst Pharmaceuticals (CPRX) United States $1.874B 18.24
Fusion Pharmaceuticals (FUSN) Canada $1.827B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.693B 0.00
Evotec AG (EVO) Germany $1.690B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.605B 24.12
Ardelyx (ARDX) United States $1.571B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.514B 0.00
Xencor (XNCR) United States $1.455B 0.00
Pacira BioSciences (PCRX) United States $1.382B 13.14
Soleno Therapeutics (SLNO) United States $1.375B 0.00
4D Molecular Therapeutics (FDMT) United States $1.300B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.265B 0.00
Enliven Therapeutics (ELVN) United States $1.126B 0.00
Collegium Pharmaceutical (COLL) United States $1.121B 6.70
Cassava Sciences (SAVA) United States $1.042B 0.00
Cronos Group (CRON) Canada $1.009B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.931B 14.51
Relay Therapeutics (RLAY) United States $0.905B 0.00
Ocular Therapeutix (OCUL) United States $0.898B 0.00
USANA Health Sciences (USNA) United States $0.890B 14.55
ARS Pharmaceuticals (SPRY) United States $0.870B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $0.831B 0.00
ProKidney (PROK) United States $0.773B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.743B 0.00
Sage Therapeutics (SAGE) United States $0.709B 0.00
Lyell Immunopharma (LYEL) United States $0.706B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.668B 0.00
Silence Therapeutics (SLN) United Kingdom $0.656B 0.00
Harrow (HROW) United States $0.633B 0.00
Exscientia (EXAI) United Kingdom $0.567B 0.00
Savara (SVRA) United States $0.564B 0.00
Siga Technologies (SIGA) United States $0.531B 6.78
Altimmune (ALT) United States $0.520B 0.00
Heron Therapeutics (HRTX) United States $0.518B 0.00
OmniAb (OABI) United States $0.516B 0.00
Lexeo Therapeutics (LXEO) United States $0.509B 0.00
Bioventus (BVS) United States $0.504B 19.30
Corbus Pharmaceuticals Holdings (CRBP) United States $0.481B 0.00
KalVista Pharmaceuticals (KALV) United States $0.477B 0.00
Korro Bio (KRRO) United States $0.453B 0.00
Larimar Therapeutics (LRMR) United States $0.452B 0.00
Verve Therapeutics (VERV) United States $0.443B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.406B 0.00
Esperion Therapeutics (ESPR) United States $0.404B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.363B 0.00
Fractyl Health (GUTS) United States $0.357B 0.00
Organogenesis (ORGO) United States $0.349B 65.75
Tourmaline Bio (TRML) United States $0.345B 0.00
Nanobiotix S.A (NBTX) France $0.311B 0.00
Nektar Therapeutics (NKTR) United States $0.301B 0.00
Nature's Sunshine Products (NATR) United States $0.289B 18.37
Xeris Biopharma Holdings (XERS) United States $0.286B 0.00
ESSA Pharma (EPIX) Canada $0.283B 0.00
Aquestive Therapeutics (AQST) United States $0.279B 0.00
Black Diamond Therapeutics (BDTX) United States $0.275B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.255B 0.00
Century Therapeutics (IPSC) United States $0.252B 0.00
Acrivon Therapeutics (ACRV) United States $0.245B 0.00
Metagenomi (MGX) United States $0.245B 0.00
Foghorn Therapeutics (FHTX) United States $0.240B 0.00
Aldeyra Therapeutics (ALDX) United States $0.232B 0.00
Akebia Therapeutics (AKBA) United States $0.231B 0.00
Prelude Therapeutics (PRLD) United States $0.225B 0.00
Pyxis Oncology (PYXS) United States $0.224B 0.00
Eliem Therapeutics (ELYM) United States $0.216B 0.00
Conduit Pharmaceuticals (CDT) United States $0.210B 0.00
Avita Medical (RCEL) United States $0.209B 0.00
Telomir Pharmaceuticals (TELO) United States $0.200B 0.00
Zevra Therapeutics (ZVRA) United States $0.195B 0.00
Galectin Therapeutics (GALT) United States $0.190B 0.00
Achieve Life Sciences (ACHV) Canada $0.186B 0.00
Adherex Technologies (FENC) United States $0.183B 223.33
Elite Pharmaceuticals (ELTP) United States $0.182B 17.05
Profound Medical (PROF) Canada $0.179B 0.00
Incannex Healthcare (IXHL) Australia $0.176B 0.00
Innate Pharma SA (IPHYF) France $0.176B 0.00
Cardiol Therapeutics (CRDL) Canada $0.161B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.159B 0.00
MediWound (MDWD) Israel $0.156B 0.00
VAXART, INC (VXRT) United States $0.153B 0.00
Context Therapeutics (CNTX) United States $0.150B 0.00
Regulus Therapeutics (RGLS) United States $0.132B 0.00
FibroGen (FGEN) United States $0.129B 0.00
OptiNose (OPTN) United States $0.125B 0.00
Karyopharm Therapeutics (KPTI) United States $0.124B 0.00
Citius Pharmaceuticals (CTXR) United States $0.119B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.118B 7.86
PMV Pharmaceuticals (PMVP) United States $0.105B 0.00
ProPhase Labs (PRPH) United States $0.096B 0.00
Assertio Holdings (ASRT) United States $0.095B 4.35
Relmada Therapeutics (RLMD) United States $0.092B 0.00
Vivani Medical (VANI) United States $0.092B 0.00
SCYNEXIS (SCYX) United States $0.089B 1.25
AlloVir (ALVR) United States $0.087B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.086B 0.00
Aclaris Therapeutics (ACRS) United States $0.079B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.076B 0.00
Tempest Therapeutics (TPST) United States $0.072B 0.00
Journey Medical (DERM) United States $0.072B 0.00
Champions Oncology (CSBR) United States $0.061B 0.00
Mural Oncology (MURA) Ireland $0.061B 0.00
Protara Therapeutics (TARA) United States $0.058B 0.00
Carisma Therapeutics (CARM) United States $0.056B 0.00
Nutriband (NTRB) United States $0.056B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.055B 0.00
BioLineRx (BLRX) Israel $0.055B 0.00
Inotiv (NOTV) United States $0.052B 0.00
CASI Pharmaceuticals (CASI) China $0.048B 0.00
Gain Therapeutics (GANX) United States $0.044B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.043B 0.00
NRx Pharmaceuticals (NRXP) United States $0.042B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Natural Alternatives (NAII) United States $0.041B 0.00
DURECT (DRRX) United States $0.040B 0.00
Rafael Holdings (RFL) United States $0.039B 0.00
VYNE Therapeutics (VYNE) United States $0.037B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.037B 0.00
Lipocine (LPCN) United States $0.037B 0.00
Unicycive Therapeutics (UNCY) United States $0.036B 0.00
Surrozen (SRZN) United States $0.033B 0.00
Viracta Therapeutics (VIRX) United States $0.029B 0.00
JanOne (JAN) United States $0.029B 0.00
BioVie (BIVI) United States $0.028B 0.00
Oncternal Therapeutics (ONCT) United States $0.027B 0.00
Enlivex Therapeutics (ENLV) Israel $0.026B 0.00
TherapeuticsMD (TXMD) United States $0.025B 0.00
Aptorum Group (APM) United Kingdom $0.024B 0.00
Jaguar Animal Health (JAGX) United States $0.023B 0.00
Iterum Therapeutics (ITRM) Ireland $0.022B 0.00
PolyPid (PYPD) Israel $0.022B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.021B 0.79
Indaptus Therapeutics (INDP) United States $0.020B 0.00
Lyra Therapeutics (LYRA) United States $0.020B 0.00
Alaunos Therapeutics (TCRT) United States $0.018B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Talphera (TLPH) United States $0.018B 0.00
GlycoMimetics (GLYC) United States $0.017B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.017B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.014B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.014B 0.00
CERo Therapeutics Holdings (CERO) United States $0.014B 0.00
Redhill Biopharma (RDHL) Israel $0.014B 0.00
Avalo Therapeutics (AVTX) United States $0.014B 0.00
Dominari Holdings (DOMH) United States $0.013B 0.00
Plus Therapeutics (PSTV) United States $0.012B 0.00
TransCode Therapeutics (RNAZ) United States $0.012B 0.00
Cosmos Health (COSM) Greece $0.012B 0.00
Inhibikase Therapeutics (IKT) United States $0.012B 0.00
Biomerica (BMRA) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
SHINECO (SISI) China $0.009B 0.00
Universe Pharmaceuticals INC (UPC) China $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Molecular Templates (MTEM) United States $0.008B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
Vivos Therapeutics (VVOS) United States $0.007B 0.00
Ainos (AIMD) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
XORTX Therapeutics (XRTX) Canada $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.005B 0.00
Petros Pharmaceuticals (PTPI) United States $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Phio Pharmaceuticals (PHIO) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Finch Therapeutics (FNCH) United States $0.003B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
PainReform (PRFX) Israel $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.31
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 33.85